NCT06567470

A Study With CIT-013 in RA Patients

A Phase IIa Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Trial To Investigate The Effects Of Three Dose Levels Of CIT-013 On Disease Activity In Patients With Moderately Active Rheumatoid Arthritis.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Citryll BV · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA. Participants will: Take receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	CIT-013 low dose	Subcutaneous injection
DRUG	CIT-013 high dose	Subcutaneous injection
DRUG	Placebo	Subcutaneous injection
DRUG	CIT-013 medium dose	CIT-013 medium dose

Timeline

• Start date: 2025-07-29
• Primary completion: 2027-04-01
• Completion: 2027-07-01
• First posted: 2024-08-22
• Last updated: 2026-03-25

Locations

24 sites across 5 countries: Belgium, Germany, Netherlands, Poland, Spain